NEW YORK (GenomeWeb) – Meridian Bioscience today reported a slight improvement in its fiscal third quarter sales as it missed consensus Wall Street expectations on the top and bottom lines.

The Cincinnati-based firm said that for the three months ended June 30, sales inched up to $47.2 million, an increase of a fraction of 1 percent from $47.1 million during its fiscal year 2013 third quarter and below the average analyst estimate of $48 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: issues in reproducibility, circulating DNA predicts breast cancer relapse, and more.

Because of an autoimmune disorder, a man has been shedding live polioviruses for 28 years, according to an analysis appearing in PLOS Pathogens.

Being in a long-term collaboration can increase researchers' citation rates by 17 percent, a recent analysis says.

By analyzing tweets, Canadian researchers examine the public's view of gene patenting.